Tested at the Toulouse Oncopole, therapeutic vaccines once morest cancer are under study. A hope, in particular in the fight once morest ovarian cancer, which shows results in the prevention of relapses, feeding the prospect of a cure in patients.
A hope once morest relapses
The challenge here is to reprogram the immune system of the cancer patient. A personalized vaccine once morest mutations in his tumor. ” The objective is to make the immune system recognize an antigen which will serve to protect them. If there were a few cells left in his body, the objective is that these cells cannot grow, are destroyed and therefore the patient is cured at the end“, details the professor.
The vaccine intervenes in therapy once the tumor has been removed and its mission is to prevent relapses, as explained by Professor Maha Ayyoub, who is an immunologist. ” We will analyze these tumors, see what antigens they express. The patient will follow his therapy and then his personalized vaccine will be manufactured. It’s not science fiction anymore, it’s real hope“, she confides.
Coming to market soon?
Since 2021, regarding ten patients with ENT cancers out of the planned fifty have already received a therapeutic and personalized vaccine, without any relapse. The researchers now want to launch a larger-scale study by the end of the year, with the hope of being on the market within five years.
The government has announced the launch in Paris of a center of excellence which should become an international reference site in innovation in oncology. According to the Minister of Higher Education, the idea is to bring together all the skills on the theme of oncology to better make the link between research and the arrival of therapeutic solutions.
In partnership with Europe 1.
